Richard Pulik is the Chief Financial Officer of Roivant Sciences, having joined in September 2021. He brings over 20 years of experience, previously serving as Global Head of Business Development & Licensing, Oncology at Novartis. He was a member of Novartis's Innovation Management Board and Oncology Leadership Team. Pulik has also worked at Bank of America Merrill Lynch, Monitor Group, and UBS Investment Bank, focusing on healthcare sector mergers and acquisitions.